Does Aimovig 140 mg outperform the 70 mg dose for migraines?
Clinical trials show Aimovig (erenumab) at 70 mg monthly reduces monthly migraine days by about 3.7 days in episodic migraine patients, compared to 2.3 days with placebo.[1] The 140 mg dose cuts days by 3.5 on average—nearly identical efficacy.[1] Pooled data from three phase 3 studies confirm no significant difference between doses for monthly migraine days or ≥50% responder rates.[2]
When might doctors prescribe 140 mg over 70 mg?
The FDA approves both doses for adults with episodic or chronic migraines, starting at 70 mg with an optional increase to 140 mg if response is inadequate.[3] About 20-30% of patients need the higher dose for optimal relief, per real-world studies.[4] It's not "better" universally but targets non-responders to 70 mg.
What do head-to-head studies say about 140 mg vs 70 mg?
In the pivotal LIBERTY trial, 140 mg showed slightly higher 50% response rates (43.3% vs 39.7% for 70 mg), but this wasn't statistically superior.[5] A Japanese phase 3 trial found 70 mg noninferior to 140 mg.[6] No trials prove 140 mg reduces more migraine days overall.
Are there safety differences between doses?
Both doses have similar side effects: injection-site reactions (up to 43% at 140 mg vs 36% at 70 mg), constipation (8-10%), and rare hypertension.[1][3] The 140 mg dose raises blood pressure slightly more (mean increase 0.9 mmHg vs 0.4 mmHg).[2] Constipation risk edges higher at 140 mg in some reports.[7]
How do patients tolerate and prefer each dose?
Patient surveys indicate similar satisfaction, with 70 mg preferred for fewer injections (one vs two prefilled syringes) and lower cost.[8] Switchers to 140 mg report better control in refractory cases, but adherence drops with higher doses due to convenience.[4]
Cost and access for 70 mg vs 140 mg
The 70 mg dose costs about $700 monthly (list price), while 140 mg doubles to $1,400—though copay cards often cap at $25.[9] Insurance frequently requires 70 mg failure before approving 140 mg.
[1] NEJM study on erenumab phase 2
[2] Pooled efficacy analysis
[3] FDA Aimovig label
[4] Real-world outcomes
[5] LIBERTY trial
[6] Japanese trial
[7] Safety profile review
[8] Patient-reported data
[9] GoodRx pricing